C4 Therapeutics (NASDAQ: CCCC) has announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).
According to C4, the MOMENTUM trial is part of a broader development strategy for cemsidomide, which also includes a Phase 1b study of cemsidomide—an oral IKZF1/3 degrader—in combination with elranatamab—an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. Together, these trials support cemsidomide’s use across multiple lines of treatment.
In a statement, Len Reyno, CMO of C4, commented, “Initiating the Phase 2 MOMENTUM trial, which builds upon the compelling anti-myeloma activity and differentiated safety profile established in the Phase 1 trial, is a critical step for cemsidomide to become a foundational therapy for multiple myeloma patients, who are in need of a safe, oral, and convenient treatment option. With this milestone accomplished, we are also on track to initiate the Phase 1b trial of cemsidomide in combination with elranatamab in the second quarter, as we continue to advance our regulatory strategy that could deliver two accelerated approval paths in multiple myeloma.”
